Aelis Farma first established its research and development on an exclusive collaboration with the Neurocentre Magendie in Bordeaux, one of the most respected and highly innovative Neuroscience Research centers in Europe with extensive experience in the CB1 receptor.
Recently, Aelis Farma extended its portfolio of international collaborations :
These extremely prestigious laboratories are complementary to Magendie for developing new signaling biased drugs. Thanks to this strategy, Aelis Farma has secured the most knowledge and expertise in the field of signaling specific drugs for the CB1 receptor and other similar GPCRs.
Aelis Farma was founded by Dr. Piazza and colleagues with an initial capital of 200 K€. The share capital was rapidly opened to VCs with a 1.000 K€ subscription by Inserm Transfer Initiative (ITI) as lead investor, and an additional 300 K€ was brought in by twin regional funds (ACI and Aqui Invest). Half of the capital of the lead investor ITI is held by major pharmaceutical companies, such as Sanofi Aventis and Pfizer which actively participate in ITI’s board of directors.
Aelis Farma has been granted from the regional government and associated state agencies (BPI France), 2.4 M€ of non-dilutive funds.
In collaboration with Columbia University, it has recently been granted a 3.3 MUSD financing from NIDA (National Institute on Drug Abuse) in order to finance the first clinical studies for its lead compound AEF0117 in the treatment of cannabis abuse. To comply with specific NIH requirements, Aelis Farma has set up an FCOI (Financial Conflicts of Interest) policy which can be provided upon request at the following address: firstname.lastname@example.org.